# Nektar Therapeutics (NKTR): MoatMap facts

As of 27 Oct 2026. Research data, not investment advice.

As of 27 Oct 2026, MoatMap's StockRank for Nektar Therapeutics (NKTR) is 17/100, ranked against 24,000+ stocks in 35 markets (Quality 30, Value 31, Momentum 36, each scored against its sector).

- StockRank: 17/100, a percentile across 24,000+ stocks in 35 markets (100 is best).
- Quality 30, Value 31, Momentum 36: each a 0-100 percentile within Healthcare.
- Position: #21,864 overall, #2,006 in Healthcare.
- Listing: United States, NCM; Healthcare / Biotechnology.
- Last close: 37.45 USD on 26 Oct 2026.
- Insider filings, last 180 days: directors sold USD 2.0M.

Source: https://moatmap.ai/stock/NKTR
How the scores work: https://moatmap.ai/methodology
Does StockRank work? The public record: https://moatmap.ai/decile-tracker